Importance of activated leukocyte cell adhesion molecule (ALCAM) in prostate cancer progression and metastatic dissemination.
ALCAM
bone
metastasis
prostate cancer
serum biomarker
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
29 Oct 2019
29 Oct 2019
Historique:
received:
09
05
2019
accepted:
05
09
2019
entrez:
8
11
2019
pubmed:
7
11
2019
medline:
7
11
2019
Statut:
epublish
Résumé
Activated Leukocyte Cell Adhesion Molecule (ALCAM) has been linked to the progression of numerous human cancers, where it appears to play a complex role. The current study aims to further assess the importance of ALCAM in prostate cancer and the prognostic potential of serum ALCAM as a biomarker for prostate cancer progression. Here we demonstrate enhanced levels of tissue ALCAM are associated with metastasis. Additionally, elevated serum ALCAM is indicative of progression and poorer patient outlook, and demonstrates comparable prognostic ability to PSA in terms of metastasis and prostate cancer survival. ALCAM suppression enhanced proliferation and invasiveness in PC-3 cells and motility/migration in PC-3 and LNCaP cells. ALCAM suppressed PC-3 cells were generally less responsive to HGF and displayed reduced MET transcript expression. Furthermore a recombinant human ALCAM-Fc chimera was able to inhibit LNCaP cell attachment to HECV and hFOB1.19 cells. Taken together, ALCAM appears to be a promising biomarker for prostate cancer progression, with enhanced serum expression associated with poorer prognosis. Suppression of ALCAM appears to impact cell function and cellular responsiveness to certain micro environmental factors.
Identifiants
pubmed: 31695844
doi: 10.18632/oncotarget.27279
pii: 27279
pmc: PMC6824871
doi:
Types de publication
Journal Article
Langues
eng
Pagination
6362-6377Informations de copyright
Copyright: © 2019 Sanders et al.
Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST The authors declare no conflicts of interest
Références
Hum Pathol. 2011 Dec;42(12):1946-52
pubmed: 21683980
Am J Pathol. 2000 Mar;156(3):769-74
pubmed: 10702391
Cancer Res. 2014 Mar 1;74(5):1404-15
pubmed: 24385212
PLoS One. 2012;7(6):e39018
pubmed: 22745698
Diagn Pathol. 2015 Jul 02;10:86
pubmed: 26134500
Int J Cancer. 2012 Jul 15;131(2):396-405
pubmed: 21858815
Anticancer Res. 2010 Apr;30(4):1163-8
pubmed: 20530423
Oncol Rep. 2014 Dec;32(6):2628-34
pubmed: 25270339
Cancer. 2006 Apr 1;106(7):1624-33
pubmed: 16518827
Oncology. 2012;82(6):305-12
pubmed: 22555284
Sci Rep. 2017 Jul 27;7(1):6715
pubmed: 28751715
BMC Cancer. 2012 Apr 04;12:140
pubmed: 22475274
Onco Targets Ther. 2014 Jun 11;7:969-83
pubmed: 24959084
J Pathol. 2017 Mar;241(4):475-487
pubmed: 27873306
Am J Pathol. 1998 Mar;152(3):805-13
pubmed: 9502422
Int J Cancer. 2009 May 1;124(9):2098-105
pubmed: 19142865
Breast Cancer Res. 2004;6(5):R478-87
pubmed: 15318930
J Clin Pathol. 2004 Nov;57(11):1160-4
pubmed: 15509676
Int J Cancer. 2013 Jun 1;132(11):2597-605
pubmed: 23169448
Mol Med Rep. 2015 Mar;11(3):2004-12
pubmed: 25395097
Breast Cancer Res Treat. 2011 Sep;129(2):347-60
pubmed: 20972617
J Surg Res. 2012 Sep;177(1):e15-20
pubmed: 22482754
Biomed Pharmacother. 2016 Feb;77:86-91
pubmed: 26796270
J Thorac Oncol. 2012 May;7(5):890-9
pubmed: 22722789
Int J Oncol. 2014 Sep;45(3):1304-12
pubmed: 24970050
Int J Oncol. 2016 Mar;48(3):919-28
pubmed: 26781475
J Clin Pathol. 2006 Apr;59(4):403-9
pubmed: 16484444
Anticancer Res. 2013 Jan;33(1):199-206
pubmed: 23267146
Int Wound J. 2011 Oct;8(5):500-7
pubmed: 21816001
Oncol Rep. 2008 Feb;19(2):555-61
pubmed: 18202807
FEBS Lett. 2006 May 15;580(11):2637-45
pubmed: 16650408
Oncogene. 2011 Mar 31;30(13):1577-85
pubmed: 21119604
Prostate. 2003 Jan 1;54(1):34-43
pubmed: 12481253
Breast Cancer (Auckl). 2015 Sep 23;9:81-6
pubmed: 26446295
Mol Cell Biol. 2006 Jul;26(13):5086-95
pubmed: 16782893
Br J Cancer. 2009 Aug 4;101(3):457-64
pubmed: 19603023
Mol Cancer Res. 2007 Dec;5(12):1246-53
pubmed: 18171982
Int J Cancer. 2009 Jul 1;125(1):9-14
pubmed: 19322904
J Surg Res. 2013 Jan;179(1):24-32
pubmed: 22985775
J Surg Oncol. 2011 Jan 1;103(1):57-61
pubmed: 20886585
Exp Ther Med. 2016 Jul;12(1):33-40
pubmed: 27347014
J Exp Med. 1995 Jun 1;181(6):2213-20
pubmed: 7760007
Cancer Lett. 1997 Jan 30;112(2):209-17
pubmed: 9066730
J Pathol. 2005 Feb;205(3):359-76
pubmed: 15532095
Blood. 2001 Oct 1;98(7):2134-42
pubmed: 11568000
Clin Chim Acta. 2015 Feb 20;441:156-62
pubmed: 25562819
Biomed Res Int. 2015;2015:690690
pubmed: 25918719